Peripheral T-Cell Lymphoma, Not Otherwise Specified

Peripheral T-Cell Lymphoma, Not Otherwise Specified — Trials · CancerIndex

Clinical trials

Registered studies

299 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 72
Recruiting: 44
Ph III recruiting: 7
Growth YoY: —
Industry share: 22%
Top sponsor: City of Hope Medical Center
Termination share: 29.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (41)

clinicaltrialsPublishedShowing 1–50 of 299 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06561048	Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma	recruiting	Phase 3	150	Corvus Pharmaceuticals, Inc.INDUSTRY	3	Sep 25, 2026	clinicaltrials
NCT06630091	A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study	recruiting	Phase 2	30	M.D. Anderson Cancer CenterOTHER